Short course chemotherapy for tuberculous lymphadenitis in children

Area of Science:

• Pediatric Infectious Diseases
• Mycobacterial Infections
• Clinical Pharmacology

Background:

• Tuberculosis of the lymph nodes (scrofula) is a significant global health issue in children.
• Traditional treatment protocols often involve lengthy durations and surgical interventions.
• Optimizing chemotherapy regimens is crucial for improving treatment outcomes and patient adherence.

Purpose of the Study:

• To evaluate the efficacy and tolerability of a short-course, intermittent chemotherapy regimen for pediatric tuberculous lymphadenitis.
• To assess treatment response, compliance, and adverse reactions in children receiving the regimen.
• To determine the long-term effectiveness and need for retreatment after the short-course therapy.

Main Methods:

• An open, collaborative, outpatient clinical trial was conducted.
• 168 children aged 1-12 years with confirmed tuberculous lymphadenitis were enrolled.
• Treatment involved a 6-month intermittent chemotherapy regimen including streptomycin, rifampicin, isoniazid, and pyrazinamide, with surgery limited to diagnostic biopsy.

Main Results:

• The regimen was well-tolerated with good compliance (60% completed within 15 days of the 6-month period).
• Favorable clinical responses were observed in most patients, with rapid healing of sinuses and abscesses.
• After 36 months of follow-up, only 3% of patients required retreatment for tuberculosis.

Conclusions:

• A six-month short-course chemotherapy regimen is effective for treating tuberculous lymphadenitis in children.
• The regimen demonstrates good tolerability and a low rate of relapse or need for re-treatment.
• This approach offers a successful and manageable treatment strategy for pediatric scrofula.